• Explore /
  • Poster
  • / Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

Abstract Poster

Authors

null

Naixin Ding

Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China

Naixin Ding , Lijun Zhao , Shuai Zhang , Ninglei Qiu , Xue Song , Cheng Kong , Ning Jiang , Yang Zhao , Jianfeng Huang , Feng Jiang , Ming Jiang , Zihao Zhu , Rong Yin , Binhui Ren , Xiangzhi Zhu , Ming Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

ChiCTR2100045361

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8054)

DOI

10.1200/JCO.2024.42.16_suppl.8054

Abstract #

8054

Poster Bd #

316

Abstract Disclosures

Similar Posters

First Author: Zerui Zhao

Poster

2018 ASCO Annual Meeting

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

First Author: Nathaniel R. Evans

First Author: John M. Varlotto

First Author: Matt D. Galsky